ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Introduction

The National Cancer Institute (NCI) would like to know about your experiences with the Experimental Therapeutics Clinical Trials Network (ETCTN) over the past grant year (April 2014 - March 2015).

Your input will help NCI assess and refine the ETCTN processes and identify areas for improvement.

The survey will ask questions about ETCTN processes and activities and trial portfolio. It should take approximately **15** minutes to complete.

Your responses are confidential and all results will be reported in the aggregate. Your participation and responses will have no bearing on your ETCTN grant, or any future interactions with NCI.

We thank you for your assistance!

To continue and begin the survey, click the "Next" button below.

Next >

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

OMB# 0925-0046-09
Exp. Date: 05/31/2016

Privacy Statement and Consent

Collection of this information is authorized by The Public Health Service Act, Section 411 (42 USC 285a). Participation is voluntary and there are no penalties for not participating or withdrawing from the study at any time. The information collected in this study will be kept private to the extent provided by law. Names and other identifiers will not appear in any report of the study. Information provided will be combined for all study participants and reported as summaries. You are being contacted by User-Centered Design, Inc. via email to complete this instrument so that we can gain feedback from you on your experiences and recommendations regarding the implementation of the ETCTN program.

Please click the "Next" button if you consent to taking this survey.

Public reporting burden for this collection of information is estimated to average **15** minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 208927974, ATTN: PRA (0925-0046-09). Do not return the completed form to this address.

Next >

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

5% Complete

Unsolicited Letter of Intent (LOI) Process for ETCTN Trials

*This set of questions asks you about your opinion of the **unsolicited** letter of intent (LOI) process.*

1. How aware are you of the **unsolicited LOI process** used in the ETCTN?

Not very aware				Very aware
○	○	○	○	○

2. How satisfied are you with the **unsolicited LOI process** in terms of ...

	Not very satisfied				Very satisfied	Don't know
Transparency of the unsolicited LOI submission process	○	○	○	○	○	○
Transparency of the unsolicited LOI review process	○	○	○	○	○	○
Efficiency of the unsolicited LOI process	○	○	○	○	○	○
Communication received from NCI about the unsolicited LOI process	○	○	○	○	○	○
Number of drugs available to investigators to develop quality LOIs	○	○	○	○	○	○
Clarity of which drugs are available for unsolicited LOIs	○	○	○	○	○	○

2a. Please describe any changes NCI could make to increase your satisfaction with the unsolicited LOI process.

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

15% Complete

3. In the past grant year of the ETCTN (April 2014 - March 2015), which of the following steps have you or others at your site participated in for **unsolicited LOIs**? (Select all that apply.)

	Submitted an unsolicited LOI	Had an unsolicited LOI approved	Submitted a protocol	Had a protocol reviewed	Activated a protocol
I have ...	☐	☐	☐	☐	☐
A colleague of mine has ...	☐	☐	☐	☐	☐

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

Note: 3a appears conditionally, populated with any items selected for "I have…" in Q3.



ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

20% Complete

3a. What is your level of satisfaction for these phases of the unsolicited LOI process that you were involved with?

	Not very satisfied				Very satisfied
Submitted an unsolicited LOI	○	○	○	○	○
LOI review process	○	○	○	○	○
Submitted a protocol	○	○	○	○	○
Protocol review process	○	○	○	○	○
Activated a protocol	○	○	○	○	○

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

25% Complete

Project Team Member Applications and Drug Development Plan to Develop ETCTN Trials

This set of questions asks you about your opinion of the Drug Development Project Team Member Application DDP/ (PTMA) process used to submit LOIs and protocols.

4. How aware are you of the Drug Development PTMA process (DDP/PTMA) used in the ETCTN?

Not very aware				Very aware
○	○	○	○	○

5. How much do you agree or disagree with the following statements about the DDP/PTMA process?

The DDP/PTMA process ...	Strongly disagree	Disagree	Agree	Strongly agree	Don't know
streamlines the development of early phase trials.	○	○	○	○	○
encourages multidisciplinary teams.	○	○	○	○	○
is a fair process to develop early phase trials.	○	○	○	○	○
has reduced my workload in comparison to other early phase trial processes.	○	○	○	○	○
Overall, I am satisfied with the DDP/PTMA process.	○	○	○	○	○

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

30% Complete

6. In the past grant year of the ETCTN (April 2014 - March 2015), which of the following steps have you or others at your site participated in for the DDP/PTMA process? (Select all that apply.)

	Submitted a Project Team Member Application (PTMA)	Participated in a Drug Development Plan	Been a Co-Leader for a Drug Development Plan	Submitted a letter of intent (LOI)	Submitted a protocol	Activated a protocol
I have ...	☐	☐	☐	☐	☐	☐
Others at my site have ...	☐	☐	☐	☐	☐	☐

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

Note: 6a and 6b appear conditionally; 6a is populated with any items selected for "I have…" in Q6. 6b appears if 6a appears.

Attachment_C12_ECTCN_PI_survey





Note: 7a appears conditionally if "have not opened" is selected for any protocol in Q7.



ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

50% Complete

8. Based on your experiences in the past grant year, how satisfied are you with the following aspects of opening an ETCTN trial at your center?

	Not very satisfied				Very satisfied
Communication received about trial while it was in the pipeline	○	○	○	○	○
Communication received from NCI during the process to open a trial	○	○	○	○	○
Time required to open a trial	○	○	○	○	○
Workload required to open a trial	○	○	○	○	○
Time required to maintain a study	○	○	○	○	○
Interactions with CTSU	○	○	○	○	○
Interactions with CIRB	○	○	○	○	○
Interactions with Theradex	○	○	○	○	○

8a. Please describe any changes NCI could make to increase your satisfaction with opening ETCTN trials at your site.

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

55% Complete

ETCTN Trial Portfolio

9. ETCTN protocols are intended to be innovative and are not to be duplicative of research funded by industry or other resources.

Below is a list of ETCTN protocols that were activated during the past grant year. For each protocol, please indicate whether or not you consider the trial to be answering an important scientific question?

	Not important scientific question				Important scientific question	Don't know
Protocol 1	○	○	○	○	○	○
Protocol 2	○	○	○	○	○	○
Protocol 3	○	○	○	○	○	○
... Protocol n	○	○	○	○	○	○

10. Looking at the list of trials above, to what degree are you satisfied with the overall portfolio of activated protocols in the ETCTN?

Not satisfied				Very satisfied
○	○	○	○	○

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

60% Complete

11. Below is a list of considerations about the ETCTN portfolio.

Please indicate how satisfied you are with each topic with respect to the ETCTN portfolio of trials.

	Not satisfied				Very satisfied
Number of trials in portfolio	○	○	○	○	○
Number of trials available for my center to open	○	○	○	○	○
Representation of therapeutic classes	○	○	○	○	○
Balance between scientific areas	○	○	○	○	○
Lack of duplication with research conducted by industry or other sources	○	○	○	○	○
Importance of scientific questions addressed	○	○	○	○	○
Integration of preclinical findings	○	○	○	○	○

11a. Please describe any changes NCI could make to increase your satisfaction with the portfolio of trials.

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

65% Complete

12. What changes would you like to see in the emphasis of different scientific areas in trials in the ETCTN portfolio?

	Less emphasis	About the same emphasis	More emphasis
Angiogenesis	○	○	○
Immunotherapy	○	○	○
Molecular characterizations of tumor features	○	○	○
Organ dysfunction	○	○	○
Organ dysfunction	○	○	○
Pharmacokinetics	○	○	○
Signal transduction	○	○	○

12a. If other, please describe:

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

70% Complete

Network Readiness and Satisfaction with the ETCTN

13. Overall, how ready do you believe each of the groups below were to participate in the ETCTN **at the beginning of the grant year** in April 2014?

	Not ready				Very read	Don't know
Your center	○	○	○	○	○	○
The ETCTN overall	○	○	○	○	○	○

14. Overall, how ready do you believe each of the groups below is **now** to participate in the ETCTN?

	Not ready				Very read	Don't know
Your center	○	○	○	○	○	○
The ETCTN overall	○	○	○	○	○	○

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

75% Complete

15. Please review the statements below and indicate how much you agree or disagree with each.

	Strongly disagree				Strongly agree
There are enough trials activated in the ETCTN to reach our center's accrual goals.	○	○	○	○	○
Overall I am satisfied with the progress made over the ETCTN's first year.	○	○	○	○	○
I expect most concerns that I have with the ETCTN in the first year will get worked out in the remaining years of the grant.	○	○	○	○	○
There is strong collaboration among the different centers in the ETCTN.	○	○	○	○	○
The collaboration with other centers in the ETCTN is productive.	○	○	○	○	○
My center has a team-based approach for generating ideas for early phase trials.	○	○	○	○	○
Our center has made substantial changes to its processes to accommodate the ETCTN.	○	○	○	○	○
The ETCTN opens up career opportunities for junior investigators at our center.	○	○	○	○	○
Overall, the NCI leadership is responsive to the ETCTN grantees' needs and input.	○	○	○	○	○

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

80% Complete

16. Below is a list of potential benefits to be achieved via the ETCTN network.

Please indicate if you think that each of the potential benefits is:

- More likely to occur with *ETCTN trials*,
- More likely to occur with *other investigator-initiated trials at your center*
  OR
- Equally likely to occur with *other investigator-initiated trials **and** with ETCTN trials*

	More Likely to Occur With **ETCTN** Trials at my Center	More Likely to Occur With **Other** Investigator-Initiated Trials at my Center	Likely to Occur **Equally** With Other Investigator-Initiated Trials *AND* ETCTN Trials
Obtain IRB approval quickly.	○	○	○
Activate trials quickly at my center.	○	○	○
Participate in scientifically important trials.	○	○	○
Access drugs early in their development.	○	○	○
Participate in trials that will help advance my career.	○	○	○
Enroll patients to trials at the projected accrual rate.	○	○	○
Provide my patients access to a wide variety of early phase clinical trial options.	○	○	○
Collaborate with investigators at other centers.	○	○	○
Collaborate with researchers from other disciplines.	○	○	○

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

85% Complete

Social Network Collaborations

We would like to learn more about your work with other researchers that are involved in the ETCTN.

17. Please look at the list of ETCTN organization members below and indicate a "yes" for those you had direct collaboration with over the past year (either developing protocols or opening trials).

ETCTN Lead Academic Organizations and Affiliates	Yes	No
Translational Genomics Research Institute	○	○
City of Hope Comprehensive Cancer Center	○	○
UC Davis Comprehensive Cancer Center	○	○
USC Norris Comprehensive Cancer Center	○	○
University of Colorado Cancer Center - Anschutz Cancer Pavilion	○	○
Yale Cancer Center	○	○
H. Lee Moffitt Cancer Center and Research Institute	○	○
Emory University/Winship Cancer Institute	○	○
University of Chicago	○	○
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center	○	○
National Cancer Institute Developmental Therapeutics Clinic	○	○
University of Maryland Greenbaum Cancer Center	○	○
Dana-Farber Cancer Center	○	○
Massachusetts General Hospital	○	○
Wayne State University/Karmanos Cancer Institute	○	○
Mayo Clinic Rochester	○	○
Washington University	○	○
Rutgers University - Cancer Institute of New Jersey	○	○
Roswell Park Cancer Institute	○	○
Duke University	○	○
UNC Chapel Hill	○	○
Case Western Reserve University	○	○
Cleveland Clinic Foundation	○	○
Ohio State University Comprehensive Cancer Center	○	○
Fox Chase Cancer Center	○	○
University of Pittsburgh Cancer Institute	○	○
Vanderbilt-Ingram Cancer Center	○	○
University of Texas MD Anderson Cancer Center	○	○
Virginia Commonwealth University	○	○
University Wisconsin Carbone Cancer Center	○	○
British Columbia Cancer Agency	○	○
Juravinski Cancer Center	○	○
University Health Network/Princess Margaret Cancer Center	○	○

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

Opt-out of survey

90% Complete

Demographics

The next set of questions asks about your background and experience with cancer research.

18. Please indicate your sex:

- Female
- Male

19. Please indicate your ethnicity:

- Hispanic or Latino
- Not Hispanic or Latino

20. Please indicate your race (mark one or more of the following):

- American Indian or Alaska Native
- Asian
- Black or African American
- Native Hawaiian or Other Pacific Islander
- White

21. Please indicate your scientific specialty?

22. How long have you been involved with ...

	1-5 years	6-10 years	11-15 years	16-20 years	20+ years
Early phase clinical trials					
Cancer research					
Your center					

23. Other than NCI, where have you received funding for cancer research? (Select all that apply.)

- Pharmaceutical industry
- Pharmaceutical industry
- Biotechnology companies
- Department of Veteran Affairs
- Department of Defense

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com


ETCTN
Team Driven. Cancer Therapy Focused.
Experimental Therapeutics Clinical Trials Network
National Cancer Institute at the National Institutes of Health
Opt-out of survey
95% Complete
24. Do you have any final comments about ETCTN that you would like to share?
< Back
Submit Survey >
Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.
If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com


ETCTN
Team Driven. Cancer Therapy Focused.
Experimental Therapeutics Clinical Trials Network
National Cancer Institute at the National Institutes of Health
Opt-out of survey
100% Complete
Thank you for completing this survey!
Your answers have been submitted securely.
We appreciate your feedback regarding the ETCTN.
Your feedback will help us refine the ETCTN and identify areas for improvement.
If you would like a summary of the findings after the survey closes,
please send an email to JenniferHuang@westat.com
You may now close this window.
Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.
If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com